ArticleScientific reports2025
Increased circulating heat shock protein Hsp70 serum levels as a potential biomarker in bronchial asthma patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Vanin-1: a potential diagnostic biomarker linked to oxidative stress imbalance in asthma.BMC pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 70 kDa major stress-inducible member of the heat shock protein 70 family Hsp70 plays an important pathogenic role in inflammatory and autoimmune diseases, including bronchial asthma, and therefore the detection of the levels of the circulating chaperone in serum or plasma could be employed as a diagnostic and prognostic marker. The prospective open single-center study enrolled 78 adult bronchial asthma patients and age-matched healthy volunteers (n = 78). Serum HSP70 levels were measured using the ELISA Kit. Serum concentrations of HSP70 as detected by the R&D Systems Hsp70 ELISA in asthmatics patients were significantly higher as compared to control subjects constituting 31.2 ng/ml (p < 0.001) and were negatively correlated with FEV1 (forced expiratory volume in 1 s) and FEV1/FVC in all patients with bronchial asthma. When compared the chaperone levels in non-eosinophilic and eosinophilic (> 150 cells/µL) asthma patients, statistical significance was detected (p < 0.05). Analysis revealed a significant increase of cytokines (IL-4, IL-17, IL-25, IL-33) and TSLP in bronchial asthma patients. Strong correlation was observed between the Hsp70 level and smoking (p < 0.001), but not with age and gender: In conclusion, increased Hsp70 levels in serum of asthmatic patients may serve as a potential biomarker of the disease pending further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.